| Literature DB >> 32462234 |
Marta Dąbrowska1, Magdalena Arcimowicz2, Elżbieta M Grabczak1, Olga Truba1, Aleksandra Rybka1, Katarzyna Białek-Gosk1, Karolina Klimowicz1, Barbara Jamróz3, K Niemczyk3, Rafał Krenke1.
Abstract
PURPOSE: Upper airway cough syndrome (UACS), described as chronic cough (CC) associated with allergic (AR), non-allergic rhinitis (NAR) or chronic rhinosinusitis (CRS), is one of the major causes of CC. We aimed to characterize a cohort of UACS patients with special attention to differences between patients with AR and NAR.Entities:
Keywords: Allergic rhinitis; Chronic cough; Non-allergic rhinitis; Rhinosinusitis; Upper airway cough syndrome
Mesh:
Year: 2020 PMID: 32462234 PMCID: PMC7496056 DOI: 10.1007/s00405-020-06071-y
Source DB: PubMed Journal: Eur Arch Otorhinolaryngol ISSN: 0937-4477 Impact factor: 2.503
Fig. 1Upper airway symptoms in patients with upper airway cough syndrome
Fig. 2Abnormalities in sinus computed tomography in patients with upper airway cough syndrome
Fig. 3Relative distribution of allergic rhinitis, non-allergic rhinitis and rhinosinusitis in the investigated cohort with chronic cough and upper airway cough syndrome
Fig. 4Sensitization to aeroallergens in patients with upper airway cough syndrome due to allergic rhinitis
Comparison of clinical and biochemical parameters in patients with UACS due to allergic and non-allergic rhinitis
| Evaluated data | Allergic rhinitis | Non-allergic rhinits | ||
|---|---|---|---|---|
| Demographic data | Age (years) | 52 (33–61) | 56 (38–64) | ns |
| Gender F/M | 44/15 | 54/30 | ns | |
| BMI (kg/m2) | 26.6 (24.4–31.1) | 27.3 (23.9–30) | ns | |
| Smoking history ExS/NS | 17/42 | 26/58 | ns | |
| Cough characteristics | Duration of cough (months) | 50 (18–128) | 48 (24–120) | ns |
| Dry/productive/both | 35/11/13 | 43/28/13 | ns | |
| Severity on VAS (mm) | 61 (44–73) | 59 (42–77) | ns | |
| LCQ score (points) | 11.5 (8.6–13) | 11.25 (9.1–13.8) | ns | |
| Symptoms of UACS | Rhinorrhea | 38 (64%) | 50 (59%) | ns |
| Sneezing | 11 (19%) | 17 (20%) | ns | |
| Nasal congestion | 29 (49%) | 55 (65%) | ns | |
| Facial pain | 5 (8%) | 8 (10%) | ns | |
| Smell dysfunction | 5 (8%) | 3 (4%) | ns | |
| Post nasal drip | 37 (63%) | 40 (48%) | ns | |
| Sinus CT abnormalities | Nasal septum deviation | 17/47 (36%) | 55/69 (79%) | 0.00002 |
| Hypertrophy of sinus mucosa > 3 mm | 20/47 (43%) | 42/69 (61%) | ns | |
| Turbinate hyperthrophy | 15/47 (32%) | 47/69 (68%) | 0.0003 | |
| Polyps | 11/47 (23%) | 11/69 (16%) | ns | |
| Lund-Mackay score (points) | 1 (0–3) | 4 (0–6) | ns | |
| Diagnosis of chronic rhinosinusitis | 7 (5%) | 10 (7%) | ns | |
| Comorbidities | Asthma | 32 (54%) | 29 (35%) | 0.019 |
| GER | 37 (63%) | 47 (56%) | ns | |
| Other | 6 (10%) | 15 (18%) | ns | |
| Single cough cause | 5 (8%) | 15 (18%) | ns | |
| Blood tests | WBC (× 103/uL) | 6.0 (5.0–6.9) | 6.3 (5.4- 7.1) | ns |
| Eos count (per uL) | 141 (85–236) | 160 (96–256) | ns | |
| Total IgE (IU/mL) | 23.5 (5.3–45.8) | 21.5 (10–68) | ns | |
| FeNO | (ppb) | 14.9 (11.8–22.7) | 13.1 (10.1–24.6) | ns |
Data are presented as numbers (and percentages) or median and interquartile range unless otherwise stated
F female, M male, ExS ex-smoker, NS non-smoker, BMI body mass index, VAS visual analogue scale, LCQ Leicester Cough Questionnaire, NAEB non-asthmatic eosinophilic bronchitis, WBC white blood cells, Eos eosinophils, FeNO fractional exhaled nitric oxide